Who is sponsoring NCT06790823?

NCT06790823 is sponsored by Shiraz University of Medical Sciences.

What drugs are being tested in NCT06790823?

Interventions in NCT06790823: The probiotic supplement (Moodamin capsuls), Placebo.

What condition does NCT06790823 study?

NCT06790823 studies Depressive Disorder, Depressive Disorder, Major Depressive Disorder.

Is NCT06790823 still recruiting?

NCT06790823 is currently completed. Last updated 13 June 2025.

Last reviewed 2025-06-13 · How we verify

NCT06790823

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Probiotic Supplement on Improvement of Depressive Symptoms in Patients With Substance-Induced Depressive Disorder

Completed Phase 1, PHASE2 Last updated 13 June 2025

What this trial tests

Phase 1, PHASE2 trial testing The probiotic supplement (Moodamin capsuls) in Depressive Disorder in 40 participants. Completed in 12 April 2023.

Timeline

15 July 2022

Primary endpoint
12 April 2023

12 April 2023

Quick facts

Lead sponsor	Shiraz University of Medical Sciences
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	40
Start date	15 July 2022
Primary completion	12 April 2023
Estimated completion	12 April 2023
Sites	1 location across Iran

Drugs / interventions tested

The probiotic supplement (Moodamin capsuls) — full drug profile →
Placebo

Conditions studied

Depressive Disorder — all drugs for Depressive Disorder →
Depressive Disorder, Major Depressive Disorder — all drugs for Depressive Disorder, Major Depressive Disorder →

Sponsor

Shiraz University of Medical Sciences

Who can join

Adults 18 to 70, any sex, with Depressive Disorder or Depressive Disorder, Major Depressive Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the potential of probiotics as a therapeutic intervention for Substance-Induced Depressive Disorder (SIDD). The primary question the study aims to answer is: Can a four-week course of probiotics improve depressive symptoms and alter immune markers in patients diagnosed with SIDD, compared to a placebo? The study uses a double-blind, placebo-controlled, randomized clinical trial design with 40 participants to explore this question by measuring clinical outcomes using BDI and HAM-A and immunological markers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of probiotic supplement on improvement of depressive symptoms in patients with substance-induced depressive disorder: a randomized, double-blind, placebo-controlled clinical trial.
Mosavat SH, Sahraian A, Kalani M, Namjoyan F, et al · · 2026 · PMID 41826906 · DOI 10.1186/s12888-026-07903-7

Verify or expand the search:

Other recruiting trials for Depressive Disorder

Currently open trials in the same condition.

NCT07290153 — Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC · recruiting
NCT07100951 — Comparing Brief Psychoanalytic Couple Therapy and Emotionally Focused Therapy in Reducing Relationship Distress · NA · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT06901739 — Therapeutic Potential of a Synbiotic to Improve Mental Health in Subjects With Obesity. · NA · recruiting
NCT06724666 — Transdiagnostic Internet-delivered Intervention for Adolescents With Anxiety and Depression · NA · recruiting

Other Shiraz University of Medical Sciences trials

Trials by the same sponsor.

NCT07254221 — Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients · Phase 4 · not yet recruiting
NCT06509893 — Ticagrelore Alone Post PCI · Phase 4 · recruiting
NCT05876819 — Quality of Care and Welfare Services for Disabled Middle Older Adults in Iran Lebanon · enrolling by invitation
NCT06979427 — CTFFR and Prediction of Non-Significant CAD Lesions · NA · recruiting
NCT05711004 — Efficacy of Education Via Phone-based Text Messaging (SMS) on Patients With Uncontrolled Hypertension · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06790823 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shiraz University of Medical Sciences
Last refreshed: 13 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06790823.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing